The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
<p>Abstract</p> <p/> <p>GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects. We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.</p> <p>Me...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-03-01
|
| Series: | Respiratory Research |
| Online Access: | http://respiratory-research.com/content/11/1/26 |